Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients
- PMID: 25722948
- PMCID: PMC4321393
- DOI: 10.1002/brb3.294
Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients
Abstract
Background: Attention to and perception of physical sensations and somatic states can significantly influence reporting of complaints and symptoms in the context of clinical care and randomized trials. Although anxiety and high neuroticism are known to increase the frequency and severity of complaints, it is not known if other personality dimensions or genes associated with cognitive function or sympathetic tone can influence complaints. Genetic variation in catechol-O-methyltransferase (COMT) is associated with anxiety, personality, pain, and response to placebo treatment. We hypothesized that the association of complaint reporting with personality might be modified by variation in the COMT val158met genotype.
Methods: We administered a standard 25-item complaint survey weekly over 3-weeks to a convenience sample of 187 irritable bowel syndrome patients enrolled in a placebo intervention trial and conducted a repeated measures analysis.
Results: We found that complaint severity rating, our primary outcome, was negatively associated with the personality measures of conscientiousness (β = -0.31 SE 0.11, P = 0.003) and agreeableness (β = -0.38 SE 0.12, P = 0.002) and was positively associated with neuroticism (β = 0.24 SE 0.09, P = 0.005) and anxiety (β = 0.48 SE 0.09, P < 0.0001). We also found a significant interaction effect of COMT met alleles (β = -32.5 SE 14.1, P = 0.021). in patients genotyped for COMT val158met (N = 87) specifically COMT × conscientiousness (β = 0.73 SE 0.26, P = 0.0042) and COMT × anxiety (β = -0.42 SE 0.16, P = 0.0078) interaction effects.
Conclusion: These findings potentially broaden our understanding of the factors underlying clinical complaints to include the personality dimension of conscientiousness and its modification by COMT.
Keywords: COMT; Catechol-O-methyltransferase; complaints; conscientiousness; personality.
Similar articles
-
COMT polymorphisms and anxiety-related personality traits.Neuropsychopharmacology. 2005 Nov;30(11):2092-102. doi: 10.1038/sj.npp.1300787. Neuropsychopharmacology. 2005. PMID: 15956988
-
The relationship between the val158met catechol-O-methyltransferase (COMT) polymorphism and irritable bowel syndrome.PLoS One. 2011 Mar 18;6(3):e18035. doi: 10.1371/journal.pone.0018035. PLoS One. 2011. PMID: 21437260 Free PMC article.
-
Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome.PLoS One. 2012;7(10):e48135. doi: 10.1371/journal.pone.0048135. Epub 2012 Oct 23. PLoS One. 2012. PMID: 23110189 Free PMC article.
-
Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study.J Psychiatr Res. 2011 Mar;45(3):309-21. doi: 10.1016/j.jpsychires.2010.07.004. Epub 2010 Jul 27. J Psychiatr Res. 2011. PMID: 20667552 Review.
-
The role of the catechol-O-methyltransferase (COMT) gene in personality and related psychopathological disorders.CNS Neurol Disord Drug Targets. 2012 May;11(3):236-50. doi: 10.2174/187152712800672382. CNS Neurol Disord Drug Targets. 2012. PMID: 22483293 Free PMC article. Review.
Cited by
-
How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions.Pain Rep. 2019 Jun 7;4(3):e699. doi: 10.1097/PR9.0000000000000699. eCollection 2019 May-Jun. Pain Rep. 2019. PMID: 31583340 Free PMC article.
-
Placebo effects and the molecular biological components involved.Gen Psychiatr. 2019 Sep 6;32(5):e100089. doi: 10.1136/gpsych-2019-100089. eCollection 2019. Gen Psychiatr. 2019. PMID: 31552390 Free PMC article. Review.
-
COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel Syndrome.Nurs Res. 2017 Mar/Apr;66(2):75-84. doi: 10.1097/NNR.0000000000000199. Nurs Res. 2017. PMID: 28252569 Free PMC article.
-
Can Pharmacological Conditioning as an Add-On Treatment Optimize Standard Pharmacological Treatment in Patients with Recent-Onset Rheumatoid Arthritis? A Proof-of-Principle Randomized Clinical Trial.Pharmaceuticals (Basel). 2024 Jan 13;17(1):110. doi: 10.3390/ph17010110. Pharmaceuticals (Basel). 2024. PMID: 38256943 Free PMC article.
-
Attitudes and Perceptions Toward Authorized Deception: A Pilot Comparison of Healthy Controls and Fibromyalgia Patients.Pain Med. 2020 Apr 1;21(4):794-802. doi: 10.1093/pm/pnz081. Pain Med. 2020. PMID: 31009537 Free PMC article.
References
-
- Amanzio M, Corazzini LL, Vase L. Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146:261–269. - PubMed
-
- Aoki J, Iwahashi K, Ishigooka J. Ikeda K. Association study on catechol-O-methyltransferase (COMT) Val158Met gene polymorphism and NEO-FFI. Psychiatry Res. 2011;187:312–313. - PubMed
-
- Barsky AJ, Saintfort R, Rogers MP. Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622–627. - PubMed
-
- Beck AT, Epstein N, Brown G. Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 1988;56:893–897. - PubMed
-
- Conboy LA, Wasserman RH, Jacobson EE, Davis RB, Legedza AT, Park M, et al. Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp. Clin. Trials. 2006;27:123–134. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous